Nancy Allbritton's Biography

Nancy Allbritton, Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering, University of Washington in Seattle

Nancy L. Allbritton is the Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering at the University of Washington in Seattle.

Her research focuses on the development of novel technologies for applications in single-cell analysis, micro-arrays and fluidics, and organ-on-chip and has resulted in over 180 full-length journal publications and patents and led to 15 commercial products. Her research program has been well funded by the National Institutes of Health with $60 million in grant funding since 1994. Four companies have been formed based on her research discoveries: Protein Simple (acquired by Bio-Techne in 2014 for $308M), Intellego (subsequently integrated into International Rectifier), Cell Microsystems (www.cellmicrosystems.com), and Altis Biosystems (www.altisbiosystems.com). Dr. Allbritton is a Fellow of the American Association for the Advancement of Science, the American Institute for Medical & Biological Engineering, and the National Academy of Inventors. She obtained her B.S. in physics from Louisiana State University, M.D. from Johns Hopkins University, and Ph.D. in Medical Physics/Medical Engineering from the Massachusetts Institute of Technology, with a postdoctoral fellowship at Stanford University.

Microraft Array Platform for the Selection of Lymphocytes Based on Target-Cell Killing

Tuesday, 27 September 2016 at 13:30

Add to Calendar ▼2016-09-27 13:30:002016-09-27 14:30:00Europe/LondonMicroraft Array Platform for the Selection of Lymphocytes Based on Target-Cell KillingSELECTBIOenquiries@selectbiosciences.com

Adoptive cellular therapy (ACT) is an emerging therapeutic in which cytotoxic T lymphocytes (CTLs) that recognize tumor cell epitopes are introduced into patients providing immunity against the cancer cells. For ACT to succeed, CTLs with high tumor-killing efficiency must be identified, isolated, and characterized. Current technologies do not enable simultaneous assay of cell behavior or killing followed by recovery of the most efficient killer cells. A microraft array technology that measures the ability of individual T cells to lyse a population of target cells followed by sorting of living cells into a multi-well plate for expansion and characterization was developed. The microraft array platform was combined with image processing and analysis algorithms to track and monitor killing assays over many hours. Automated cell collection was incorporated into the platform for facile cell collection from the array. As a proof of principle, human T cells directed against an influenza antigen were co-cultured with antigen presenting target cells on the microraft arrays. Target cell killing was measured by tracking the appearance of dead cells on each microraft over time. Microrafts with a single CTL demonstrating the greatest rate of target cell death were identified, cloned, and influenza-antigen reactivity confirmed. The platform is readily modified to measure the antigen-specific activity of individual cells within a bulk CTL culture or the cell heterogeneity within a population of gene-engineered T cells.

Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics: Companies, Technologies and CommercializationSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors